<DOC>
	<DOC>NCT02382510</DOC>
	<brief_summary>This multiple ascending dose study is to determine the safety and bronchodilator activity of TRN-157 in 59 mild and moderate asthmatics.</brief_summary>
	<brief_title>Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Patients who meet the following criteria will be considered eligible to participate in the study: The patient is ≥ 18 and &lt; 70 years of age, and gives informed consent Clinical diagnosis of mild to moderate asthma of at least 6 months duration and age of onset &lt; 50 years Presently using ICS at moderate doses (equivalent to 200800 µg of budesonide or 88500 µg of fluticasone daily) ≥ 12% and ≥ 200 mL improvement in FEV1 to 4 puffs albuterol by metereddose inhaler (MDI) at screening visit Patient is willing to use acceptable form of birth control during trial and for one month thereafter Ability to measure morning (AM) peak expiratory flow (PEF) on schedule using electronic peak flow meter (EPFM) and to complete the study diary correctly at least 70% of the time during the runin period After 7 day withdrawal from LABA therapy and overnight withdrawal from SABA therapy (except rescue medication), patient has between 55% 80% of predicted FEV1 at CV2 A patient meeting any of the following criteria is not eligible for enrollment in the study: A clinical diagnosis of chronic obstructive pulmonary disease (COPD), chronic bronchitis, bronchiectasis, or other significant pulmonary disease other than asthma History of upper or lower respiratory infection within 4 weeks of screening History of asthma exacerbation requiring oral or systemic corticosteroids or hospital admission within 6 months of screening History of myocardial infarction, or cardiac conduction abnormalities, including but not limited to atrial fibrillation, and paroxysmal atrial tachycardia Hospitalization due to cardiac failure within the last 6 months History of narrow angle glaucoma or obstructive uropathy Current smokers or vapers, or former smokers with &gt; 10 packyear (selfreported) history of smoking Patients who presently use the following medications will not be eligible for participation: Longacting muscarinic receptor antagonist (LAMA) LABA (but may be withdrawn and converted to SABA x 7 days prior to entry) Leukotriene pathway blockers AntiIgE antibody (Xolair) within last 6 months prior to CV1 Phosphodiesterase 4 (PDE4) inhibitors (e.g., Roflumilast) Cromolyn Methylxanthines (e.g., aminophylline and theophylline) 5Lipoxygenase inhibitor (e.g., Zileuton) Allergies to LAMA therapies History of lifethreatening asthma exacerbation requiring ICU admission, mechanical ventilation, or tracheostomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>